Wei Wu

Wei Wu

Auto-generated profile, based on publicly available information

Wei Wu

Department of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2017 in Science Signaling
Verified
Journal Article
Closed access
PDF file
WWWei Wu
Wei Wu
FSFubiao Shi
Fubiao Shi
DLDianxin Liu
Dianxin Liu
RCRyan P. Ceddia
Ryan P. Ceddia
RGRobert Gaffin
Robert Gaffin
SCSheila Collins
Sheila Collins
In addition to controlling blood pressure, cardiac natriuretic peptides (NPs) can stimulate lipolysis in adipocytes and promote the “browning” of white adipose tissue. NPs may also increase the oxidative capacity of skeletal muscle. To unravel the contribution of NP-stimulated metabolism in adipose tissue compared to that in muscle in vivo, we generated mice with tissue-specific deletion of the NP clearance receptor, NPRC, in adipose tissue (NprcAKO) or in skeletal muscle (NprcMKO). We showed that, similar to Nprc null mice, NprcAKO mice, but not NprcMKO mice, were resistant to obesity induced by a high-fat diet. NprcAKO mice exhibited increased energy expenditure, improved insulin sensitivity, and increased glucose uptake into brown fat. These mice were also protected from diet-induced hepatic steatosis and visceral fat inflammation. These findings support the conclusion that NPRC in adipose tissue is a critical regulator of energy metabolism and suggest that inhibiting this receptor may be an important avenue to explore for combating metabolic disease.

1 January 2019 in World Neurosurgery
Verified
Journal Article
Closed access
XLXiaoqing Li
Xiaoqing Li
WWWei Wu
Wei Wu
QMQing Miao
Qing Miao
MHMin He
Min He
SZShuo Zhang
Shuo Zhang
HYHongying Ye
Hongying Ye

28 July 2021 in Frontiers in Endocrinology
Verified
Journal Article
Open access
WWWei Wu
Wei Wu
QSQuanya Sun
Quanya Sun
XZXiaoming Zhu
Xiaoming Zhu
BXBoni Xiang
Boni Xiang
Qiongyue ZhangQiongyue Zhang
Qiongyue Zhang
HYHongying Ye
Hongying Ye
Context: Hypothalamic obesity (HO) is a severe complication following craniopharyngioma, but studies regarding the sequelae in adult-onset patients with craniopharyngioma are sparse.Objective: The objective of the study was to describe weight changes after surgical treatment in adult-onset craniopharyngioma patients and to analyze risk factors for postoperative weight gain and HO.Subjects and Method: A retrospective analysis was conducted of 120 adult-onset patients who underwent surgery for craniopharyngioma and follow-up at the institution of the authors between January 2018 and September 2020. Clinical characteristics, anthropometric data, image features, treatment modalities, and endocrine indices were collected. Multivariable logistic regression analysis was used to identify independent risk factors for postoperative weight gain and HO.Results: Forty-nine (40.8%) patients had clinically meaningful weight gain (≥5%) in a median follow-up time of 12.0 months (range 1.0–41.0 months) after surgery. The mean postoperative weight gain in this subgroup was 17.59 ± 12.28 (%). Weight gain continued in the first year following surgery. Patients with lower preoperative BMI [OR 0.78, 95% CI (0.67–0.90), P = 0.001] and the adamantinomatous subtype [OR 3.46, 95% CI (1.02–11.76), P = 0.047] were more likely to experience postoperative weight gain ≥5%. The prevalence of HO was 19.2% preoperatively and increased to 29.2% at last follow-up postoperatively. Only preoperative BMI [OR 2.51, 95% CI (1.64–3.85), P < 0.001] was identified as an independent risk factor for postoperative HO.Conclusions: HO is a common complication in patients with adult-onset craniopharyngioma. Patients with higher preoperative BMI had a greater risk for developing HO postoperatively.

7 March 2018 in Molecular Medicine Reports
Verified
Journal Article
Open access
PDF file
WWWei Wu
Wei Wu
BLBao‑Hua Liu
Bao‑Hua Liu
CXCheng‑Long Xie
Cheng‑Long Xie
XXXiao‑Dong Xia
Xiao‑Dong Xia
YZYan‑Mei Zhang
Yan‑Mei Zhang
N-acetyl cysteine (NAC) has been extensively reported to exert neuroprotective effects on the central nervous system. Oxidative stress may contribute to the underlying mechanisms causing Alzheimer's disease (AD). The effect of NAC against oxidative stress injury was investigated in a cellular model of AD in the present study and the underlying mechanisms were revealed. The neuroprotective action of NAC (1, 10, 100 and 1,000 µmol/l) on a cellular model of AD [hydrogen peroxide (H2O2)‑induced (3, 30 and 300 µmol/l) toxicity in primary rat hippocampus neurons] demonstrated the underlying mechanisms. Cytotoxicity was measured using the MTT assay, and light microscopy and the dichloro-dihydro-fluorescein diacetate method were used to detect the reactive oxygen species (ROS) levels. Furthermore, the levels of mitogen-activated protein kinases (MAPKs) signal transduction and tau protein phosphorylation were measured via western blotting. NAC (100 µmol/l) protected hippocampus neurons against H2O2‑mediated toxicity, as evidenced by enhanced cell viability. Using MTT assay and light microscopy for the observation of cell death, NAC ameliorated cell viability, which was induced by H2O2 injury (P<0.05). NAC was found to mitigate the excessive production of ROS (P<0.05). Another mechanism involved in the neuroprotective action of NAC may be its ability to inhibit MAPK signal transduction following H2O2 exposure. In addition, NAC may protect cells against H2O2‑induced toxicity by attenuating increased tau phosphorylation. Thus, the protective ability of NAC is hypothesized to result from inhibition of oxidative stress and downregulation of MAPK signal transduction and tau phosphorylation.

17 February 2025 in Expert Opinion on Drug Safety
Verified
Journal Article
Closed access
YLYanbo Li
Yanbo Li
BLBo Liu
Bo Liu
WWWei Wu
Wei Wu
JLJian Li
Jian Li
Topical minoxidil, approved by the FDA in the 1980s, has been widely used to manage androgenetic alopecia. While effective, several adverse events (AEs) related to its use, especially those not well-documented on product labels, remain a concern. This study aimed to evaluate the safety of topical minoxidil by analyzing AEs reported in the FDA Adverse Event Reporting System (FAERS) from 2004 to 2024, focusing on identifying potential risk signals not highlighted on current product labels. Adverse event reports (AERs) from FAERS, where topical minoxidil was identified as the primary suspect, were analyzed. Disproportionality analysis methods, Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-Item Gamma Poisson Shrinker (MGPS), were used to assess the relationship between minoxidil and reported AEs. Among 45,130 reports, most were from males (50.88%) and showed a significant increase in incidents since 2015. Newly identified AEs, such as application site acne and cysts, were observed. These AEs are not well represented on product labels. The study identified previously unreported AEs linked to topical minoxidil, underscoring the need for updated patient information and regulatory reassessment to enhance safety and inform clinical practices.